ChromaDex Corporation (OTCBB: CDXC) an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, today announced its financial results for the first quarter of 2012.
ChromaDex announced total revenues, prepared in accordance with United States Generally Accepted Accounting Principles ("GAAP"), of approximately $1.8 million and a net loss attributable to common stockholders of $0.05 per share for the three-month period ended March 31, 2012. As of March 31, 2012, cash, cash equivalents, and marketable securities totaled over $5.8 million.
"In the first quarter we launched our BluScience™ line of dietary supplements into a major drug chain and a specialty health and nutrition chain," stated Jeffrey Himmel, CEO of ChromaDex. "In addition, we initiated distribution of our BluScience™ products to a national pharmaceutical distributor and a leading online retailer."
"During the first quarter, we began to supply our patented pTeroPure® ingredient to the equine supplement market. This is another step in achieving our goal to build ChromaDex into a leader in the natural products industry," said Frank Jaksch, Chief Scientific Officer of ChromaDex.
Living in food deserts during early childhood raises long-term obesity risk